Evidence map›Paper›PMID 25136512›Full record

ArticleEJNMMI research2014

Imaging of α7 nicotinic acetylcholine receptors in brain and cerebral vasculature of juvenile pigs with [(18)F]NS14490.

Sven Rötering, Winnie Deuther-Conrad, Paul Cumming, Cornelius K Donat, Matthias Scheunemann, Steffen Fischer, Guoming Xiong, Jörg Steinbach, Dan Peters, Osama Sabri and 2 more

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Sven RöteringInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstr. 15, Leipzig 04318, Germany.
Winnie Deuther-ConradInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstr. 15, Leipzig 04318, Germany.
Paul CummingDepartment of Nuclear Medicine, Friedrich-Alexander-Universität, Ulmenweg 18, Erlangen 91054, Germany ; Department of Pharmacology and Neuroscience, Copenhagen University, Blegdamsvej 3B, Copenhagen 2200, Denmark.
Cornelius K DonatInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstr. 15, Leipzig 04318, Germany.
Matthias ScheunemannInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstr. 15, Leipzig 04318, Germany.
Steffen FischerInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstr. 15, Leipzig 04318, Germany.
Guoming XiongDepartment of Nuclear Medicine, Ludwig-Maximilians-Universität, Marchioninistr. 15, Munich 83177, Germany.
Jörg SteinbachInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstr. 15, Leipzig 04318, Germany.
Dan PetersDanPET AB, Rosenstigen 7, Malmö SE-21619, Sweden.
Osama SabriDepartment of Nuclear Medicine, Universität Leipzig, Liebigstr. 18, Leipzig 04103, Germany.
Jan BuceriusDepartment of Nuclear Medicine, Maastricht University Medical Center, P. Debeylaan 25, Maastricht 6229, The Netherlands ; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, P. Debeylaan 25, Maastricht 6229, The Netherlands ; Department of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelstr. 30, Aachen 52074, Germany.
Peter BrustInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstr. 15, Leipzig 04318, Germany.
Helmholtz-Zentrum Dresden-Rossendorf · DEDanpet (Sweden) · SEFriedrich-Alexander-Universität Erlangen-Nürnberg · DELeipzig University · DELudwig-Maximilians-Universität München · DEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe α7 nicotinic acetylcholine receptor (nAChR) is an important molecular target in neuropsychiatry and oncology. Development of applicable highly specific radiotracers has been challenging due to comparably low protein expression. To identify novel ligands as candidates for positron emission tomography (PET), a library of diazabicyclononane compounds was screened regarding affinity and specificity towards α7 nAChRs. From these, [(18)F]NS14490 has been shown to yield reliable results in organ distribution studies; however, the radiosynthesis of [(18)F]NS14490 required optimization and automation to obtain the radiotracer in quantities allowing dynamic PET studies in piglets.

methodsAutomated radiosynthesis of [(18)F]NS14490 has been performed by [(18)F]fluorination with the tosylate precursor in the TRACERlab™ FX F-N synthesis module (Waukesha, WI, USA). After optimization, the radiochemical yield of [(18)F]NS14490 was consistently approximately 35%, and the total synthesis time was about 90 min. The radiotracer was prepared with >92% radiochemical purity, and the specific activity at the end of the synthesis was 226 ± 68 GBq μmol(-1). PET measurements were performed in young pigs to investigate the metabolic stability and cerebral binding of [(18)F]NS14490 without and with administration of the α7 nAChR partial agonist NS6740 in baseline and blocking conditions.

resultsThe total distribution volume relative to the metabolite-corrected arterial input was 3.5 to 4.0 mL g(-1) throughout the telencephalon and was reduced to 2.6 mL g(-1) in animals treated with NS6740. Assuming complete blockade, this displacement indicated a binding potential (BPND) of approximately 0.5 in the brain of living pigs. In addition, evidence for specific binding in major brain arteries has been obtained.

conclusion[(18)F]NS14490 is not only comparable to other preclinically investigated PET radiotracers for imaging of α7 nAChR in brain but also could be a potential PET radiotracer for imaging of α7 nAChR in vulnerable plaques of diseased vessels.

Indexed as

Alpha7 nicotinic acetylcholine receptorsAlzheimer's diseaseBlood-brain barrierCancerDiazabicyclononaneMetabolismPETStroke

Identifiers

PMID25136512
PMCPMC4129469
OpenAlexW2039153684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.